BACKGROUND: This study was designed to adapt the Elixhauser comorbidity index for 4 cancer-specific populations (breast, prostate, lung, and colorectal) and compare 3 versions of the Elixhauser comorbidity score (individual comorbidities, summary comorbidity score, and cancer-specific summary comorbidity score) with 3 versions of the Charlson comorbidity score for predicting 2-year survival with 4 types of cancer. METHODS: This cohort study used Texas Cancer Registry-linked Medicare data from 2005 to 2011 for older patients diagnosed with breast (n 5 19,082), prostate (n 5 23,044), lung (n 5 26,047), or colorectal cancer (n 5 16,693). For each cancer cohort, the data were split into training and validation cohorts. In the training cohort, competing risk regression was used to model the association of Elixhauser comorbidities with 2-year noncancer mortality, and cancer-specific weights were derived for each comorbidity. In the validation cohort, competing risk regression was used to compare 3 versions of the Elixhauser comorbidity score with 3 versions of the Charlson comorbidity score. Model performance was evaluated with c statistics. RESULTS: The 2-year noncancer mortality rates were 14.5% (lung cancer), 11.5% (colorectal cancer), 5.7% (breast cancer), and 4.1% (prostate cancer). Cancer-specific Elixhauser comorbidity scores (c 5 0.773 for breast cancer, c 5 0.772 for prostate cancer, c 5 0.579 for lung cancer, and c 5 0.680 for colorectal cancer) performed slightly better than cancer-specific Charlson comorbidity scores (ie, the National Cancer Institute combined index; c 5 0.762 for breast cancer, c 5 0.767 for prostate cancer, c 5 0.578 for lung cancer, and c 5 0.674 for colorectal cancer). Individual Elixhauser comorbidities performed best (c 5 0.779 for breast cancer, c 5 0.783 for prostate cancer, c 5 0.587 for lung cancer, and c 5 0.687 for colorectal cancer). CONCLUSIONS: The cancer-specific Elixhauser comorbidity score performed as well as or slightly better than the cancer-specific Charlson comorbidity score in predicting 2-year survival. If the sample size permits, using individual Elixhauser comorbidities may be the best way to control for confounding in cancer outcomes research.
INTRODUCTION
Comorbidity is common among cancer patients and affects the diagnosis, treatment, and outcomes of cancer. 1 Because of the increased risk of comorbidities in the aging cancer population, improved methods for assessing comorbidities are needed. Accurate measurement and control of comorbidities in cancer outcomes research are crucial to reduce confounding. Different methods such as the Charlson comorbidity score, the National Cancer Institute (NCI) combined index, and the Elixhauser comorbidity score are available to control for comorbidities. [2] [3] [4] A comorbidity measure developed or adapted for a specific disease population performs better than a generic score. 5 The Charlson score includes 17 comorbidities; it was originally developed to predict 1-year mortality with all inpatient data from one hospital, and it was validated in patients with breast cancer from another hospital. 2 Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, Klabunde et al 3 modified the Charlson comorbidity index for patients with breast, prostate, colorectal, and lung cancer. This cancer-specific Charlson comorbidity score, called the NCI combined index, outperformed the original Charlson comorbidity score in predicting 2-year survival in cancer patients.
The Elixhauser comorbidity index includes 29 comorbidities. 4, 6 A systematic review found that the Elixhauser comorbidity score performs better than the Charlson comorbidity score in predicting mortality beyond 30 days. 7 In patients with oral and colorectal cancer, 2 studies reported that the Elixhauser comorbidity score performed better than the Charlson comorbidity score in predicting 3-year survival. 8, 9 In contrast, one study showed better performance of the Charlson comorbidity score in patients with bladder cancer. 10 No consensus exists on the optimal method for defining comorbidities in cancer. 1, 11 Although the Charlson comorbidity index has been adapted for cancer patients, the Elixhauser comorbidity index has not. Moreover, both the Charlson and Elixhauser comorbidity measures can be used as 1) individual comorbidities, 2) summary scores using generic weights, and 3) cancerspecific summary scores using cancer-specific weights.
Modifying the Elixhauser comorbidity index for cancer-specific populations may improve its performance in this population. Therefore, the study objectives were to 1) adapt the Elixhauser comorbidity index for 4 cancerspecific populations and 2) compare the performance of 3 versions of the Elixhauser comorbidity score with 3 versions of the Charlson comorbidity score in predicting 2-year survival for patients with the 4 most common cancers diagnosed in the United States (breast, prostate, lung, and colorectal cancer).
MATERIALS AND METHODS

Data Source and Study Sample
The study used Texas Cancer Registry (TCR)-linked Medicare data from 2005 to 2011. The TCR is linked with Medicare data under the guidance of the NCI, TCR, and Centers for Medicare and Medicaid Services. This linked data set provides detailed information on elderly adults with cancer in Texas, and approximately 98% of all people aged 65 years or older in the TCR are matched with Medicare enrollment and claims files. Similarly to SEER files, the TCR provides detailed information on patient demographics and the clinical characteristics of cancer, such as the stage of disease, tumor size, first course of therapy, and cause of death (ie, cancer or not cancer). 12 Medicare data provide information on a patient's health care utilization. The Medicare files used for this study included the denominator file, the Medicare Provider Analysis and Review file for inpatient claims, the carrier claims file, and the outpatient standard analytical file.
Four cancer-specific cohorts were developed by the inclusion of older adults (age > 65 years) diagnosed with breast, prostate, lung, or colorectal cancer. Patients were included in the final cohorts if they had continuous enrollment in Medicare Parts A and B, with no health maintenance organization enrollment, in the year before the cancer diagnosis.
Outcome
The study outcome was 2-year noncancer mortality; cancer mortality was treated as a competing risk. The underlying cause of death was determined from death-certificate data as recorded by the TCR. The TCR is equivalent to SEER in timeliness, completeness, and data quality. 13 The agreement between the cause of death reviewed from the medical charts and the SEER-reported cause of death is greater than 95%. 14, 15 Noncancer mortality was selected as an outcome because of our focus on deaths attributable to comorbid conditions; this method was consistent with the Charlson, Klabunde, and NCI methodologies. 2, 3, 16 Covariates Age, sex (for lung and colorectal cancer), and cancer stage (local, regional, or distant) were included as covariates.
Comorbidity Scores
Medicare inpatient and outpatient claims data were used to identify comorbidities. We used a baseline of 1 year to define comorbidity scores. A comorbidity was identified when the patient had at least 1 diagnosis from the inpatient file or at least 2 distinct diagnoses recorded >30 days apart from the outpatient file in the 365 days before the cancer diagnosis.
3,17
Charlson comorbidity score
The Charlson comorbidity index includes 17 comorbidities. The original Charlson comorbidity score was derived from the inpatient data of 607 patients from New York Hospital-Cornell Medical Center and was validated in 685 women with breast cancer from Yale New Haven Hospital. Weights for each comorbidity were derived and summed to obtain a summary comorbidity score. Klabunde et al 3 adapted the Charlson comorbidity index for 4 cancers and derived cancer-specific weights. This cancer-specific Charlson comorbidity score was termed the NCI combined index. The documentation and SAS codes for the NCI combined index are available on the NCI Web site. 18 In this study, we used 3 versions of the Charlson comorbidity score: 1) individual Charlson comorbidities, 2) a summary Charlson comorbidity score derived from the original weights, 2 and 3) a cancer-specific summary Charlson comorbidity score (ie, the NCI combined index) derived from cancer-specific weights. The Elixhauser comorbidity index includes 29 disease conditions. 4 Van Walraven et al 6 developed weights for 29 Elixhauser comorbidities to operationalize the score as a summary score. However, the weights were derived from inpatient data from a hospital, and they were not cancerspecific. Therefore, we first constructed cancer-specific weights for the Elixhauser comorbidity score. To do so, we performed a 50:50 split to derive training and validation cohorts for each cancer. The derivation cohort was used to obtain cancer-specific weights for Elixhauser comorbidities. We derived weights for each cancer cohort separately. We used 3 versions of the Elixhauser comorbidity index: 1) individual Elixhauser comorbidities, 2) a summary Elixhauser comorbidity score derived from the van Walraven weights, 6 and 3) a cancer-specific Elixhauser comorbidity score derived from cancer-specific weights.
Statistical Analyses
Descriptive statistics were performed for the 4 cancerspecific cohorts to describe the demographics, death rates, and comorbidity prevalence. A training sample was used to derive cancer-specific weights for the Elixhauser comorbidity score. The Fine-Gray competing risk model was used to model the association of Elixhauser comorbidities with 2-year survival while controlling for age, sex, and stage of cancer. The b coefficients obtained from the competing risk model were multiplied by 10 and were rounded to the nearest integer to obtain weights for each comorbidity. 19 This was done separately for each cancer cohort.
We used the validation sample to compare the performance of 3 versions of the Elixhauser comorbidity score with 3 versions of the Charlson comorbidity score. The Fine-Gray competing risk model was used to predict 2-year noncancer mortality. First, we constructed a baseline model that included age, sex, and cancer stage. Six models were constructed: 3 for the Elixhauser comorbidity score and 3 for the Charlson comorbidity score. All models were compared with c statistics and the Akaike information criterion (AIC). Statistical comparisons between c statistics were performed with bootstrapped estimates with 1000 replicates.
All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina), Stata 13.2 (StataCorp, Inc, College Station, Texas), and R (version 3.4.0). This study was considered non-human subject research and was deemed exempt by the institutional review board of the University of Texas Medical Branch.
RESULTS
Descriptive Statistics
The overall study sample included 19,082 patients with breast cancer, 23,044 patients with prostate cancer, 26,047 patients with lung cancer, and 16,963 patients with colorectal cancer. Table 1 reports the descriptive statistics for the 4 cancers by the stage of diagnosis. The mean age of the patients ranged from 73.6 6 5.8 (prostate cancer) to 77.2 6 7.3 years (colorectal cancer). More than 92% of the patients with breast and prostate cancer, 83% of the patients with colorectal cancer, and 50% of the patients with lung cancer were diagnosed with cancer at the local or regional stage. The overall 2-year mortality rate was highest for lung cancer (73.9%), which was followed by colorectal cancer (33.8%), breast cancer (12.1%), and prostate cancer (8.1%). The 2-year noncancer mortality rate followed a similar pattern: 14.5% for lung cancer, 11.5% for colorectal cancer, 5.7% for Charlson comorbidities, diabetes without chronic complications, chronic pulmonary disease, congestive heart failure, diabetes with complications, and moderate or severe renal disease were the most prevalent conditions. Among the Elixhauser comorbidities, hypertension, uncomplicated diabetes, chronic pulmonary disease, hypothyroidism, and deficiency anemia were the most prevalent conditions.
Adapting the Elixhauser Comorbidity Score for Cancer Patients
The training data set included 9391 patients with breast cancer, 11,346 patients with prostate cancer, 12,804 patients with lung cancer, and 8314 patients with colorectal cancer. Using training data sets for the 4 cancers, we derived cancer-specific weights for Elixhauser comorbidities (Table 3 ). The weights for the comorbidities differed slightly by cancer type. For instance, the weights for congestive heart failure were 7 for the breast cancer cohort, 9 for the prostate cancer cohort, 1 for the lung cancer cohort, and 3 for the colorectal cancer cohort. Four sets of cancer-specific weights were then used to calculate cancerspecific summary Elixhauser comorbidity scores.
Comparative Performance of the Elixhauser and Charlson Comorbidity Scores: 6 Models
The validation data set included 9691 patients with breast cancer, 11,698 patients with prostate cancer, 13,243 patients with lung cancer, and 8649 patients with colorectal cancer. Table 4 reports the c statistics of the different models. The c statistics of the baseline model, which included age, sex, and cancer stage, were 0.722 for the breast cancer cohort, 0.725 for the prostate cancer cohort, 0.548 for the lung cancer cohort, and 0.629 for the colorectal cancer cohort. The addition of any comorbidity score to the baseline model improved the c statistics for all 4 cancers (Table 4) . For both the Elixhauser and Charlson comorbidity indices, a model with individual comorbidities performed better than models with summary comorbidity scores ( Table 4) . Individual Elixhauser comorbidities included in the model performed better than Charlson comorbidities used as individual variables (0.779 vs 0.770 for breast cancer, P 5 .028; 0.783 vs 0.772 for prostate cancer, P 5 .011; 0.587 vs 0.579 for lung cancer, P 5 .046; and 0.687 vs 0.679 for colorectal cancer, P 5 .042). Among the summary comorbidity scores, a cancer-specific summary Elixhauser comorbidity score (0.773 for breast cancer, 0.772 for prostate cancer, 0.579 for lung cancer, and 0.680 for colorectal cancer) performed as well as or slightly better than a summary Elixhauser comorbidity score (0.764 for breast cancer, 0.771 for prostate cancer, 0.580 for lung cancer, and 0.677 for colorectal cancer), a summary Charlson comorbidity score (0.763 for breast Table 4 ). AIC results are presented in Table 5 . AIC results were similar to those from c statistics. A cancer-specific summary Elixhauser comorbidity score had a slightly lower AIC value than other summary comorbidity scores, and this indicated better performance.
DISCUSSION
We adapted the Elixhauser comorbidity index for cancer patients and compared the performance of 3 versions of the Elixhauser comorbidity index with 3 versions of the Charlson comorbidity index in their ability to predict 2-year survival. For both the Charlson and Elixhauser comorbidity indices, the use of individual comorbidities performed better than summary comorbidity scores; Elixhauser comorbidities as individual variables performed the best. Among summary scores, we found that the cancer-specific summary Elixhauser comorbidity score performed as well as or slightly better than generic and cancer-specific summary Charlson comorbidity scores. Klabunde et al 3 derived cancer-specific weights for the Charlson comorbidity score. However, to our knowledge, this is the first study to adapt the Elixhauser comorbidity score for cancer patients by the derivation of 4 cancer-specific weights and to compare them with 3 commonly used versions of the Charlson comorbidity score. Several studies have shown that comorbidity scores predict survival and health-related quality of life in patients with colorectal cancer. of comorbidities (0, 1, 2, 3, 4, or 5) rather than a summary score or individual comorbidities. 10 Our findings extend the evidence on the performance of comorbidity indices in cancer outcomes research via our comprehensive comparison for 4 common types of cancer.
Elixhauser comorbidities as individual variables had the best performance, and they were followed by the cancerspecific summary Elixhauser comorbidity score. This result is consistent with prior studies showing that individual comorbidities have the best performance. 19, 22 Moreover, the better performance of the Elixhauser comorbidity index may be attributed to the fact that it has more comorbidities than the Charlson comorbidity index. If sample size is not an issue, the use of individual comorbidities should be the first choice. However, summary comorbidity scores can be useful for describing the overall burden of comorbidities in a single measure, and they offer advantages when the sample size is low and a higher statistical power is desired.
Comorbidities are common in older adults with cancer and affect the disease progression, stage at diagnosis, treatment, and outcomes. No gold-standard method exists to control for comorbidities in cancer outcomes research. 11 One study identified 21 separate approaches to measuring comorbidities in cancer patients. The authors concluded that, for administrative claims data, the Charlson comorbidity score, NCI combined index, and Elixhauser comorbidity scores were the best options, and the NCI combined index may be the best because of its cancer-specific weights. 11 The cancer-specific weights that we derived for Elixhauser scores showed the same or slightly better performance than a cancer-specific Charlson comorbidity score (ie, the NCI combined index).
Some of the comorbidities (hypertension and obesity) were negatively associated with survival. This has been found in other studies. 6 The explanation may vary with the comorbidity. For example, a hypertension diagnosis might be linked to access to medical care and to an increased likelihood that elevated blood pressure is recognized and treated. An obesity diagnosis indicates an absence of cachexia, which is common in cancer patients and a poor sign. Our study had the following strengths. We operationalized comorbidity indices in different ways and used the Fine-Gray competing risk model to determine the association of comorbidities with noncancer mortality. However, our findings should be interpreted in the context of the study design. We used cancer registry data from Texas, and our findings may not be generalizable to other populations. Moreover, we used TCR-Medicare linked data, and these findings may not be applicable to patients 65 years old or younger. In agreement with the Charlson and Klabunde methods, we used noncancer mortality as an outcome. The lower c index among patients with lung cancer suggests potential limitations in applying the 1-size-fits-all approach with comorbidity scores even when cancer-specific scores are being considered. The inability to control for unknown confounders with large retrospective registry data is an inherent limitation. Because of the high correlation between summary Charlson and Elixhauser comorbidity scores, we did not use them together in the same model. Future research can compare cancerspecific Elixhauser comorbidity scores with a pharmacybased comorbidity index for cancer patients to determine whether they improve the prediction of mortality. 23 Use of the most appropriate comorbidity score will not be a panacea for controlling all confounding; several sources of cofounding, such as disease severity, functional status, social support, and health behavior, need to be controlled to make unbiased treatment estimates in observational studies. In conclusion, we adapted the summary Elixhauser comorbidity score for 4 cancer-specific populations. Elixhauser comorbidities used as individual variables in the model performed the best, and among summary scores, the cancer-specific summary Elixhauser comorbidity score performed equally as well as or slightly better than either the generic or cancer-specific Charlson comorbidity score. If the sample size allows, one should use individual Elixhauser comorbidities to control for confounding due to comorbidities in cancer outcomes research. For small samples that require using a summary comorbidity score, cancer-specific summary Elixhauser comorbidity scores or Charlson comorbidity scores work equally well. The use of comorbidity scores is growing in cancer outcomes research. With changes in coding practices (from International Classification of Diseases, Ninth Revision, Clinical Modification to International Classification of Diseases, Tenth Revision, Clinical Modification), future work should adapt algorithms to the new coding system and re-evaluate the applicability and comparative performance of comorbidity scores in cancer patients. 
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